REMARKS

The Present Invention

The present invention pertains to an antibody that is reactive with an immunogenic peptide of gp100.

The Pending Claims

Claims 1-25 are currently pending and are directed to antibodies that are reactive with an immunogenic peptide of gp100.

The Amendments to the Specification

The specification has been amended to label all amino acid and nucleotide sequences with a SEQ ID NO: of the sequence listing. The specification also has been amended throughout to delete any reference to Figures 7 and 8. The deletion of Figures 7 and 8 does not adversely affect the sufficiency of disclosure.

Conclusion

The application is considered to be in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



Carol Larcher, Reg. No. 35,243
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: October 15, 2003

M:\Clients\nih\amd\223375 Prelim Amd.doc